The effects of preoperative chemotherapy on isolated tumour cells in the blood and bone marrow of gastric cancer patients
| Autor: | Tadeusz Popiela, A Gurda, Grażyna Drabik, Piotr Kołodziejczyk, Anna Pituch-Noworolska, Antoni M. Szczepanik, Marek Sierzega, Marek Zembala, Jan Kulig |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
isolated tumour cells Cancer Research medicine.medical_specialty medicine.medical_treatment Kaplan-Meier Estimate Gastroenterology Drug Administration Schedule Blood cell Breast cancer Bone Marrow Stomach Neoplasms Internal medicine Clinical Studies Antineoplastic Combined Chemotherapy Protocols Preoperative Care medicine Humans Stomach cancer Aged Cisplatin Chemotherapy Chi-Square Distribution Surrogate endpoint business.industry gastric cancer Cancer Middle Aged Neoplastic Cells Circulating medicine.disease Surgery Treatment Outcome medicine.anatomical_structure Oncology Leukocyte Common Antigens Female Fluorouracil Bone marrow business neoadjuvant chemotherapy medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/sj.bjc.6603904 |
| Popis: | Recent studies in breast cancer suggest that monitoring the isolated tumour cells (ITC) may be used as a surrogate marker to evaluate the efficacy of systemic chemotherapy. In the present study, we have investigated the effects of preoperative chemotherapy on ITC in the blood and bone marrow of patients with potentially resectable gastric cancer. After sorting out the CD45-positive cells, the presence of ITC defined as cytokeratin-positive cells was examined before and after preoperative chemotherapy. The patients received two courses of preoperative chemotherapy with cisplatin (100 mg m(-2), day 1) and 5-fluorouracil (1000 mg m(-2), days 1-5), administered every 28 days. Fourteen of 32 (44%) patients initially diagnosed with ITC in blood and/or bone marrow were found to be negative (responders) after preoperative chemotherapy (P0.01). The incidence of ITC in bone marrow was also significantly (P0.01) reduced from 97 (31 of 32) to 53% (17 of 32). The difference between patients positive for ITC in the blood before (n=7, 22%) and after (n=5, 16%) chemotherapy was statistically insignificant. The overall 3-year survival rates were 32 and 49% in the responders and non-responders, respectively (P=0.683). These data indicate that preoperative chemotherapy can reduce the incidence of ITC in patients with gastric cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|